Inhaled corticosteroids (ICS) and to a lesser extent nasal steroids (NS) have undoubtedly revolutionised asthma therapy and improved quality of life in a cost-effective way. However, current evidence suggests that every asthmatic child on corticosteroids is at risk of hypothalamic-pituitary-adrenal axis suppression (HPAS). As most patients with this complication are asymptomatic, those most at risk should be screened. If screening is inconclusive, adrenal function testing should be performed. On the basis of its outcome the most appropriate management should be determined.

In a recently published approach to paediatric asthma management, treatment modifications included a 3-day course of rescue oral corticosteroids, intermittent use of ICS, a single ICS dose in the morning if possible, and a more prominent role for non-steroid controller medication. All these measures will protect the hypothalamic-pituitary-adrenal axis from suppression. However, the article neither recommended screening for nor suggested any management of HPAS.

Whenever exogenous corticosteroids are prescribed, endogenous cortisol production is reduced. This ‘systemic effect’ is determined by the dose, delivery device, technique, adherence, body surface area, body mass index (BMI) and duration of therapy, the number of corticosteroids being used and their pharmacokinetic characteristics, area, body mass index (BMI) and duration of therapy, the number of corticosteroids being used and their pharmacokinetic characteristics, and genetic and epigenetic factors. Age and gender are not predictors, unless the dose has not been adjusted to body surface area. At supraphysiological ICS doses, 50% of children can be expected to develop HPAS, while at physiological doses (i.e. a cortisol production rate of 3.0–10.6 mg/m²) cortisol levels are measured at 10, 15, 20, 25, 30 and 35 minutes. If metyrapone stimulation test should be performed. On the basis of its outcome the most appropriate management should be determined.

Clinicians utilising the ACTH stimulation test need to be aware of several pitfalls. Interpretation of results is assay specific. In 2015, Roche launched its Elecsys Cortisol II assay. It is more specific than the older cortisol assay and shows lower cross-reactivity, generating cortisol levels that are ~30% lower. Hypocortisolemia has even been described at physiological doses. HPAS is usually seen in all children after 6–42 months of ICS therapy, but has been observed as early as 2 months (EWZ, unpublished data, 2011). Under basal conditions no untoward effects will be apparent, because the decreased production of cortisol is balanced by the supply of exogenous corticosteroids. In the long term, the adrenal glands may atrophy. During a stressful event such as an infection, injury, burn or surgical operation, or even an asthma exacerbation, demand for cortisol may outstrip its exogenous supply. The stress can precipitate an adrenal crisis, which may lead to death. When CYP1A4 enzyme inhibitors (antiretrovirals, antifungals, calcium-channel blockers, certain antibiotics and antidepressants) are coadministered, metabolism of corticosteroids is reduced, resulting in HPAS or Cushing’s syndrome.

In order to make recommendations for diagnosis, screening and management of HPAS in asthmatic children, I have reviewed the existing literature and presented the quality of the evidence assessed in three tables. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used. It classifies the quality of the evidence as high, moderate, low or very low, with the recommendations being either strong or weak.

Management suggestions that could not be substantiated by evidence are labelled ‘ungraded best practice’.

### Diagnosis of HPAS
HPAS presents as a spectrum (Table 1). Adrenal crisis is the most devastating presentation, but occurs rarely. Chronic adrenal insufficiency (CAI) is frequently overlooked owing to its nonspecific clinical features. For these reasons it is essential to diagnose HPAS in its subclinical stage. The overnight metyrapone test should be used to make the definitive diagnosis of HPAS. If metyrapone is not available, the 0.5 µg/L, 73 m² adrenocorticotropic hormone (ACTH) stimulation test is a good second choice, provided serum cortisol levels are measured at 10, 15, 20, 25, 30 and 35 minutes. Clinicians utilising the ACTH stimulation test need to be aware of several pitfalls. Interpretation of results is assay specific. In 2015, Roche launched its Elecsys Cortisol II assay. It is more specific than the older cortisol assay and shows lower cross-reactivity, generating cortisol levels that are ~30% lower.

The pass criterion for the test therefore has to be down-adjusted to 350 nmol/L (from 500 nmol/L).

### Screening for HPAS
Screening for HPAS (Table 2) is problematic, because no useful screening test has been identified so far. Measurement of early-
morning salivary cortisone has been suggested,\textsuperscript{10} but its routine use is premature because it has not been evaluated against a gold-standard adrenal function test. Its low positive predictive value would also argue against its use. Endocrinologists diagnose adrenal insufficiency when the 08h00 - 10h00 serum cortisol level is <138 nmol/L, while a serum cortisol level of >350 nmol/L (as measured with the Elecsys Cortisol II assay) virtually excludes HPAS.\textsuperscript{21} A 06h00 - 08h00 serum cortisol level of <83 nmol/L to suggest HPAS would be ideal, but may be impractical. There is no scientific basis for labelling a level >276 nmol/L as safe.\textsuperscript{2} Given the poor performance of the serum cortisol screen, only patients at high risk should be screened. If the results are inconclusive, the patient should be referred to an endocrinologist for definitive testing.

In order to identify patients at high risk, meticulous attention should be paid to an individual asthma patient’s treatment, the corresponding doses and calculation of the total steroid dose, relating this to body surface area. In addition, cognisance needs to be taken of the child’s BMI, adherence to therapy and the ICS route of administration, as lung deposition, and hence dose, varies between devices.\textsuperscript{1,3}

### Table 1. Diagnostic features of HPAS

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Clinical features</th>
<th>Serum cortisol</th>
<th>Strength of recommendation/level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal crisis</td>
<td>Hypoglycaemia* – depressed level of consciousness/coma, convulsions; nausea (hypotension, syncope, severe weakness, abdominal pain, vomiting, backache, hyponatraemia, hyperkalaemia, hypercalcæmia)\textsuperscript{1}</td>
<td>Usually &lt;138 nmol/L</td>
<td>Strong/moderate</td>
</tr>
<tr>
<td>Chronic adrenal insufficiency</td>
<td>Lassitude, weakness, dizziness, nausea, headache, poor growth, weight loss, (orthostatic hypotension)\textsuperscript{1}</td>
<td>&lt;138 nmol/L at 08h00 - 10h00</td>
<td>Weak/very low</td>
</tr>
<tr>
<td>Subclinical hypocortisolaemia</td>
<td>Inability to respond appropriately to stress</td>
<td>&lt;138 nmol/L at 08h00 - 10h00</td>
<td>Strong/moderate</td>
</tr>
<tr>
<td>Failed adrenal function test\textsuperscript{1}</td>
<td>Inability to respond appropriately to stress 138 - 350 nmol/L at 08h00 - 10h00</td>
<td>Weak/low</td>
<td></td>
</tr>
</tbody>
</table>

HPAS = hypothalamic-pituitary-adrenal axis suppression; CAI = chronic adrenal insufficiency; ACTH = adrenocorticotrophic hormone. \textsuperscript{1}Hypoglycaemia is the most common presentation of adrenal crisis in the paediatric age group. \textsuperscript{2}These clinical/laboratory findings are classic features, but have not been described in case series. \textsuperscript{3}Metyrapone or 0.5 µg/1.73 m\textsuperscript{2} ACTH stimulation test. \textsuperscript{4}As measured by the Elecsys Cortisol II assay.

### Table 2. Screening recommendations for subclinical HPAS

<table>
<thead>
<tr>
<th>Patients at highest risk</th>
<th>Strength of recommendation/level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. On a supraphysiological total steroid dose (ICS + NS), i.e. &gt;10.6 mg HC equivalent/m\textsuperscript{2}/d (&gt;BUD 848 µg/m\textsuperscript{2}/d or &gt;FP 424 µg/m\textsuperscript{2}/d given by MDI + spacer)</td>
<td>Strong/moderate</td>
</tr>
<tr>
<td>B. On a physiological total steroid dose (≤10.6 mg HC equivalent/m\textsuperscript{2}/d) On multiple steroids</td>
<td>Strong/low</td>
</tr>
<tr>
<td>C. Adherent to ICS + NS therapy</td>
<td>Strong/moderate</td>
</tr>
<tr>
<td>D. BMI z-score &lt;0\textsuperscript{1}</td>
<td>Strong/moderate</td>
</tr>
<tr>
<td>E. On an enzyme inhibitor</td>
<td>Strong/varies with inhibitor</td>
</tr>
</tbody>
</table>

Screening test interpretation

<table>
<thead>
<tr>
<th>Serum cortisol at 08h00 - 10h00</th>
<th>Strength of recommendation/level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;138 nmol/L: hypocortisolaemia</td>
<td>Weak/low</td>
</tr>
<tr>
<td>&gt;350 nmol/L: normal axis</td>
<td>Weak/low</td>
</tr>
<tr>
<td>138 - 350 nmol/L: refer for metyrapone or 0.5 µg/1.73 m\textsuperscript{2} ACTH stimulation test</td>
<td>Strong/moderate</td>
</tr>
</tbody>
</table>

Screening frequency

| If serum cortisol > 350 nmol/L, screen 6-monthly if steroid dose not reduced | Ungraded best practice |

HPAS = hypothalamic-pituitary-adrenal axis suppression; ICS = inhaled corticosteroids; NS = nasal steroids; HC = hydrocortisone; BUD = budesonide; FP = fluticasone propionate; MDI = metered-dose inhaler; BMI = body mass index; ACTH = adrenocorticotrophic hormone. \textsuperscript{1}Clobetasol propionate, betamethasone valerate, hydrocortisone butyrate. \textsuperscript{2}BMI z-score 0 - 2 does not exclude HPAS, but <0 is more likely. \textsuperscript{3}As measured by the Elecsys Cortisol II assay.
Management of HPAS

Management of adrenal crisis is life-saving (Table 3). Treatment modification (besides hydrocortisone) for CAI or subclinical HPAS is essentially the same. The aim of the intervention is to keep the total steroid dose well within the lower-normal physiological range.

Steroid-sparing controllers available include leukotriene receptor antagonists, long-acting beta-agonists, long-acting theophylline, tiotropium bromide, and the biological agents omalizumab, mepolizumab and dupilumab. Should HPAS develop while on nasal beclomethasone or budesonide, nasal therapy should therefore be switched to one of the newer agents. However, beclomethasone is the preferred ICS/NS for any child treated with an enzyme inhibitor in addition to a steroid, because it is not metabolised by cytochrome P450. Rescue oral corticosteroids should never be given for more than 3 days and should not be provided to parents to be used when necessary.

Treatment modification for HPAS has been found to be effective. Even when ICS doses are not reduced, HPAS seems to resolve in some patients. This may be due to poor adherence to therapy or an increase in airway diameter with age, resulting in better control with reduced ICS doses.

Conclusions

Any asthmatic child on corticosteroids may develop HPAS. In the absence of clinical features, serum cortisol should be used to screen those most at risk. Screening should start 6 months into therapy and include children on supraphysiological steroid doses, those on multiple steroids or enzyme inhibitors, and those adherent to therapy or who are thin. If screening is inconclusive, adrenal function testing should be performed by a paediatric endocrinologist. Appropriate management, including asthma therapy modification, should be instituted if necessary.

Declaration. None.

Acknowledgements. None.

Author contributions. Sole author.
Funding. None.

Conflicts of interest. None.


Accepted 18 March 2019.